Trials in GI Surgery

  1. Cross trial

Carcinoma Esophagus

The CROSS trial demonstrated median overall survival (OS) of 49.4 months in the nCRT + surgery group compared to 24 months in the surgery alone cohort

The five‐year survival rates were 47% and 34%, respectively, and 29% of patients reached a pathological complete response (pCR).